What are the adverse reactions of combining trametinib and dabrafenib?

The combined use of trametinib and dabrafenib in the treatment of BRAF V600E mutated cancer patients can significantly improve the efficacy, but it may also be accompanied by a series of adverse reactions.

1.Skin reactions: rash, dry skin, itching, erythema, etc. are common adverse skin reactions. Patients should keep their bodies clean, their clothes clean, avoid using alkaline cleaning products to irritate their skin, and take medication as directed by their doctor.

2.Digestive system reactions: including diarrhea, nausea, vomiting, loss of appetite, etc. Patients should eat more light liquid or semi-liquid foods, avoid foods that can aggravate diarrhea, and take antidiarrheal drugs as directed by their doctor.

3. Fever and chills: Fever is one of the most common adverse reactions of the combination regimen of dabrafenib and trametinib, and patients may be accompanied by chills. For fever, patients should rest more, drink more water, and use physical cooling. If the fever persists, they should seek medical help immediately.

4.Fatigue and joint pain: Some patients may feel fatigue and joint pain during treatment, which affects daily activities. These adverse reactions may require dose adjustment or symptomatic treatment to alleviate them.

5.Respiratory system reactions: such as coughing, dyspnea, etc., which are more common especially in patients with lung diseases. The patient's condition should be carefully assessed before use, and patients with high collars and lung diseases should use with caution.

6.Visual problems: Dabrafenib may cause visual problems such as blurred vision and light sensitivity. Patients should protect their eyes during use and avoid prolonged exposure to strong light.

7.Cardiovascular system reactions: Trametinib may cause hypertension, and blood pressure changes need to be closely monitored.

8. Blood system reactions: Trametinib may cause hematological adverse reactions such as proteinuria, and relevant indicators need to be monitored regularly.

New malignant tumors:

During or after treatment, patients should be closely monitored for new malignancies, such as cutaneous squamous cell carcinoma and basal cell carcinoma.

When using the combination of trametinib and dabrafenib, patients should strictly follow the doctor's instructions and are not allowed to adjust the dosage or stop the medication on their own. Regular follow-up should be carried out during treatment, the occurrence of adverse reactions should be monitored, and any discomfort should be reported to the doctor in a timely manner. For serious adverse reactions, such as persistent high fever, worsening difficulty in breathing, etc., you should seek medical help immediately.